LUCA Science
Manufacturing · Japan · 11-50 Employees
View Company Info for Free
Overview
Headquarters
3-8-3 Nihonbashi Honcho, Nihonbashihonch...Website
www.luca-science.comRevenue
$6.8 MillionIndustry
ZI Rank: 1
Signal Type
Dec
Jan
Feb
Mar
Apr
May
ZI Rank
1
1
1
1
1
1
About LUCA Science
Based out of Tokyo, Japan, LUCA Science is a pre-clinical stage biopharmaceutical company with a focus on mitochondria therapies.Explore more
LUCA Science Org Chart
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is LUCA Science your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Funding: Get notified immidiatlly once LUCA Science has new funding data
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Check if LUCA Science has recently received funding, and reach out quickly before it becomes old news!
LUCA Science, which may be a good buyer, showed buying intent in Masked Content Topic
Check out if LUCA Science is spiking on competitors!
Website visits: Recent activity has been detected on your website
Earning: See what the market has to say on LUCA Science recently announced quarterly report
Click to see if LUCA Science had a recent Job posting/layoffs
Product Launch: Get notified when LUCA Science launches new products
Congratulate Masked Content for being promoted to Masked Content at LUCA Science
Recommended Actions
Introduce yourself to Masked Content, who has shown a strong intent to purchase lately
Find 2 more new buyers
Company Profile Activity
Activity Insights
LUCA Science is experiencing very low activity levels compared to other companies in the Manufacturing sector.
What does this means?
LUCA Science is drawing exceptional interest within the Manufacturing industry, suggesting notable developments or strong market momentum, learn more about LUCA Science.
LUCA Science financials insights
Gather financial insights about LUCA Science, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
2020
Series A
$9.8M
2022
Series B
$30.3M
LUCA Science Tech Stack
A closer look at the technologies used by LUCA Science
LUCA Science News & Media
LUCA Science Raises ¥3.86 Billion ($30.3 Million) in Oversubscribed Series B Financing
TOKYO--(BUSINESS WIRE)--LUCA Science, a global innovator in the development of a novel class of mitochondria biopharmaceutical agents, today announced the closing of a ¥3.86 billion (USD 30.3 million) oversubscribed Series B financing. The round was co-led by DCI Partners, 4BIO Capital and existing investor Fast Track Initiative and supported by an international syndicate of existing investors including Remiges Ventures and Nippon Venture Capital Co, and new investors including Nissay Capital,LUCA Science and Kyowa Kirin Announce Joint Research Agreement on Mitochondrial Disease Treatment With Novel Mitochondria Modality
TOKYO--(BUSINESS WIRE)--LUCA Science Inc. (LUCA Science, Tokyo, Japan) and Kyowa Kirin Co., Ltd. (Kyowa Kirin, Tokyo, Japan, TSE:4151) are pleased to announce they have entered into a research collaboration agreement on the treatment of mitochondrial diseases using platform of an innovative mitochondrial modality. Through this research collaboration, Kyowa Kirin, a leading specialty pharmaceutical company with deep disease science research knowledge based on diverse experiences in biopharmaceutLUCA Science Announces the Opening of a New Subsidiary in the UK and Expansion on the Collaboration With the University of Oxford on the Development of Novel Mitochondrial Therapeutics
TOKYO--(BUSINESS WIRE)--LUCA Science (Tokyo, Japan), a biotechnology company pioneering a novel class of mitochondrial therapeutics has announced the expansion of its international operations, with the establishment of a new wholly-owned subsidiary company in the United Kingdom. LUCA Science UK will focus on research collaborations with the University of Oxford using LUCA Science’s proprietary Mitochondria therapy in advancing treatment of intra-uterine growth restriction (IUGR) for mothers andLUCA Science Announces Joint Research With Division of Cardiology, Field of Internal Medicine, Nagoya University Graduate School of Medicine on the Development of Mitochondrial Therapy for Myocardial Infarction (Cardiac Ischemic-reperfusion Injury)
TOKYO--(BUSINESS WIRE)--LUCA Science (Tokyo, Japan), a biotechnology company pioneering a novel class of mitochondrial therapeutics, announced today that it will collaborate with the Division of Cardiology, Field of Internal Medicine, Nagoya University Graduate School of Medicine to initiate a joint research on the development of mitochondrial therapy for cardiac ischemic–reperfusion injury. Background of joint research Ischemic heart disease (myocardial infarction and angina) still remains the
Read more news
Top Manufacturing Companies
Top companies in Canada by revenue
Top companies in Australia by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding LUCA Science
Sign Up For FreeTo access detailed company insights
Based out of Tokyo, Japan, LUCA Science is a pre-clinical stage biopharmaceutical company with a focus on mitochondria therapies.... Read More
